As the specter of smallpox, the only human disease officially eradicated, still looms, a recent report emphasizes the imperative for the United States to fortify its defenses against a potential resurgence. Nearly five decades post the last recorded case, smallpox persists as a formidable concern, warranting heightened vigilance against its reemergence, whether through natural occurrences, laboratory accidents, or acts of terrorism.
The authors of the report, commissioned by the U.S. government and facilitated by the National Academies of Sciences, Engineering, and Medicine (NASEM), underscore the need for strategic investments in enhanced vaccines, diagnostics, and therapeutics to confront this lingering threat effectively. While refraining from taking a stance on the contentious issue of destroying the remaining variola virus stocks held in two secure laboratories, the report advocates for bolstered measures to counter potential outbreaks.
Drawing parallels with recent experiences combating emerging infectious diseases such as mpox and the COVID-19 pandemic, the report underscores the lessons to be learned in augmenting preparedness against smallpox. Highlighting gaps in the nation's readiness and response framework, the report urges proactive measures to address vulnerabilities exposed by past challenges.
The current existence of smallpox virus samples solely within the confines of high-security laboratories prompts renewed scrutiny over the management of these stocks, considering both accidental risks and the looming threat of bioterrorism. Amid debates over the fate of these samples, the report emphasizes the evolving landscape of the discussion, particularly with the advent of publicly available genetic sequences that could potentially enable the recreation of the virus.
Acknowledging the global ramifications of a smallpox outbreak, the report stresses the importance of international cooperation and equitable distribution of resources, particularly concerning vaccine stockpiles. Additionally, it calls for the development of safer, single-dose vaccine options to address concerns regarding immunocompromised individuals.
Moreover, the report underscores the imperative for advancing smallpox and mpox therapeutics and diagnostics to overcome existing limitations. Given the challenges posed by differential diagnosis between smallpox and related viruses, the report advocates for expanded access to specialized diagnostics to expedite outbreak responses.
Dr. Nahid Bhadelia, a co-author of the report, emphasizes the imperative for reassessing assumptions and bolstering preparedness in light of recent global health crises. With lessons learned from the COVID-19 pandemic and the mpox epidemic, she underscores the importance of proactive evaluation and adaptation to ensure robust readiness against the persistent threat of smallpox.
